



Rutland Biodynamics Ltd (Herbal Medicines)
Town Park Farm, Brooke, Rutland, LE15 8DG, UK
UK Dept of Health MHRA cGMP MIA number 28255
www.rutlandbio.com

Finished Product Certificate of Analysis

Batch: 081009-2/2

PRODUCT INFORMATION

Product common name	American Bugleweed, Gipsywort
Product Latin name	<i>Lycopus virginicus</i>
Plant part	Fresh Herb
Product code	1017H
Batch number	081009-2/2
Cultivation	Organic
Herb : Liquid Ratio	1:2
Alcoholic Strength	25%

Extracts are prepared by suitable methods using ethanol or other suitable solvents according to the General Extracts monograph of the European Pharmacopoeia (Monograph 0765). Herbal drugs and organic solvents used for the preparation of extracts comply with any relevant monograph of the Pharmacopoeia.

Herbal drugs are obtained from cultivated or wild plants. Suitable collection, cultivation, harvesting, drying, fragmentation and storage conditions are essential to guarantee the quality of herbal drugs. Herbal drugs are, as far as possible, free from impurities such as soil, dust, dirt and other contaminants such as fungal, insect and other animal contaminations in accordance with European Pharmacopoeia Monograph 1433 (Herbal Drugs).

ANALYTICAL RESULTS


Organolepsis ¹	
Appearance	Conforms to specification
Odour	Conforms to specification
Taste	Conforms to specification

1) All extracts comply with the requirements of the European Pharmacopoeia for Herbal Drug Preparations Monograph 1434. Determination according to Rutland Biodynamics SOP C22.



Rutland Biodynamics Ltd (Herbal Medicines)
 Town Park Farm, Brooke, Rutland, LE15 8DG, UK
 UK Dept of Health MHRA cGMP MIA number 28255
 www.rutlandbio.com

Finished Product Certificate of Analysis
Batch: 081009-2/2

Phytochemistry	
Thin Layer Chromatography ²	
Total dissolved solids ³	Conforms to specification
HPLC	N/A

Natural variations in the levels of constituents in different samples of a plant drug may lead to minor deviations from one chromatogram to another. The extent of deviation allowed before samples are considered unacceptable or contaminated with foreign material depends on experience and careful judgement. Samples are also evaluated in accordance with any relevant Pharmacopoeial monograph.

- 2) Determination according to Rutland Biodynamics SOP C51.
- 3) Determination according to Rutland Biodynamics SOP C72.

Microbiology ⁴	
Total Aerobic Count (<10 ⁴ cfu/ml)	Conforms to Ph. Eur.
Yeast and Mould (<10 ² cfu/ml)	Conforms to Ph. Eur.
Bile tolerant gram negative bacteria (<10 ² cfu/ml)	Conforms to Ph. Eur.
Absence of <i>Escherichia coli</i>	Conforms to Ph. Eur.

4) All extracts comply with relevant aspects of the European Monograph for Microbiological quality of herbal medicinal products for oral use (Monograph 5.1.8.). Determination according to Rutland Biodynamics SOP C61.

I hereby certify that the above tests have been carried out under my authority, under the standard operational procedures of Rutland Biodynamics Ltd. and under Good Manufacturing Practice in conformance with the Company's current certificate of compliance with Good Manufacturing Practice (MIA 28255) laid down in Directive 2003/94/EC. This certificate and the results shown apply to the tested sample only. This report may not be used by third parties, including for promotional purposes, without the prior written permission of Rutland Biodynamics Ltd.

I certify that this batch has been declared fit for release.

Signed  Kate Stokes BSc MSc MRSC Qualified Person

Date 25/10/10